TY - JOUR
T1 - Proton Pump Inhibitor Use and the Antifracture Efficacy of Alendronate
AU - Abrahamsen, Bo
AU - Eiken, Pia
AU - Eastell, Richard
PY - 2011/2/14
Y1 - 2011/2/14
N2 - BACKGROUND: Proton pump inhibitors (PPIs) are widely used in elderly patients and are frequently coadministered in users of oral bisphosphonates. Biologically, PPIs could affect the absorption of calcium, vitamin B(12), and bisphosphonates and could affect the osteoclast proton pump, thus interacting with bisphosphonate antifracture efficacy. Moreover, PPIs themselves have been linked to osteoporotic fractures. METHODS: Population-based, national register-based, open cohort study of 38 088 new alendronate sodium users with a mean duration of follow-up of 3.5 years. We related risk of hip fracture to recent pharmacy records of refill of prescriptions for alendronate. RESULTS: For hip fractures, there was statistically significant interaction with alendronate for PPI use (P
AB - BACKGROUND: Proton pump inhibitors (PPIs) are widely used in elderly patients and are frequently coadministered in users of oral bisphosphonates. Biologically, PPIs could affect the absorption of calcium, vitamin B(12), and bisphosphonates and could affect the osteoclast proton pump, thus interacting with bisphosphonate antifracture efficacy. Moreover, PPIs themselves have been linked to osteoporotic fractures. METHODS: Population-based, national register-based, open cohort study of 38 088 new alendronate sodium users with a mean duration of follow-up of 3.5 years. We related risk of hip fracture to recent pharmacy records of refill of prescriptions for alendronate. RESULTS: For hip fractures, there was statistically significant interaction with alendronate for PPI use (P
U2 - 10.1001/archinternmed.2011.20
DO - 10.1001/archinternmed.2011.20
M3 - Journal article
C2 - 21321287
SN - 1538-3679
VL - 11
SP - 998
EP - 1004
JO - Archives of Internal Medicine
JF - Archives of Internal Medicine
ER -